Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ovarian Cancer
Study results from University of Lund update understanding of ovarian cancer
August 3rd, 2009
According to recent research published in the International Journal of Gynecological Cancer, "Epidermal growth factor (EGF) Stimulates proliferation and migration in ovarian cancer cells, and high tumor expression of the EGF system correlates with poor prognosis. Epidermal growth factor upregulates urokinase plasminogen activator receptor (uPAR) on the cell surface via 3 distinct mechanisms: rapid mobilization of uPAR from detergent-resistant domains, increased mRNA, and decreased degradation." "G-protein-coupled receptor 30 (GPR30) is a newly identified membrane estrogen receptor (ER). The objective of this study was to explore the effects of 17 beta-cstradiol...
Source: Biotech Business Week (2009-08-03)
|
